ClinicalTrials.gg
CompletedNCT02253862Updated Oct 1, 2014

Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers

A Phase 1 interventional study of Tadalafil and Tipranavir in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-01.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Study to assess the effects of single-dose and steady-state tipranavir/ritonavir 500 mg/200 mg on the single-dose pharmacokinetics of tadalafil 10 mg

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Healthy male subjects aged between 18 years and 55 years inclusive
  3. Weighing at least 40 kg
  4. Volunteers must be hospitalized on day of pharmacokinetic assessments for each regimen
  5. Volunteers must be willing to complete all study-related activities
  6. Each volunteer must have a valid social security regimen
  7. Each volunteer must have acceptable medical history, physical examination and laboratory test
  8. Volunteers with negative serology

Exclusion criteria

Exclusion Criteria:

  1. History or presence of allergy to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation. (If heparin is used during pharmacokinetic (PK) sampling, subjects with a history of sensibility to heparin or heparin-induced thrombocytopenia should not be enrolled)
  2. Any finding of the medical examination (including blood pressure, pulse rate, and ) deviating from normal and of clinical relevance
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, haematological, oncological or hormonal disorders
  4. Known elevated liver enzymes in past clinical trials with any compound (experimental or marketed)
  5. laboratory abnormalities and all abnormal laboratory values >Grade 1, based on the Division of AIDS Grading Scale
  6. Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering tipranavir, ritonavir or tadalafil to the subject
  7. Volunteers who are using any form of organic nitrate, either regularly and/or intermittently ( to use tadalafil)
  8. to tadalafil, tipranavir, ritonavir or their
  9. Concurrent treatment with other experimental compounds
  10. Inadequate venous access
  11. Contraindications to tadalafil: Volunteers with mild or moderate hepatic impairment, Renal insufficiency or Cardiovascular disease (patients with a myocardial infarction within the last 90 days, unstable angina or angina occurring during sexual intercourse, patients with Class 2 or greater heart failure in the last 6 months, patients with uncontrolled arrhythmias, hypotension (\<90/50 mm Hg), or uncontrolled hypertension (>170/100 mm Hg), and patients with a stroke within the last 6 months)
  12. Clinically unacceptable result at the screening physical examination
  13. Use of medications within 30 days before study entry
  14. Patients hospitalized in a medical or social establishment, for any other reason than research
  15. People deprived of judicial or administrative freedom.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Sequential treatment

    Drug: Tadalafil · Drug: Tipranavir · Drug: Ritonavir

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) for Tadalafil

    Time frame: up to 72 hours after drug administration

  2. Plasma Concentration (Cp12h) for Tadalafil

    Time frame: 12 hours after drug administration

  3. Area Under Plasma Concentration-time Curve (AUC0-72h) for Tadalafil

    Time frame: up to 72 hours after drug administration

  4. AUC0-∞ for Tadalafil

    Time frame: up to 72 hours after drug administration

Secondary outcomes

  1. Cmax for Tipranavir and Ritonavir

    Time frame: up to 12 hours after drug administration

  2. Cp12 for Tipranavir and Ritonavir

    Time frame: 12 hours after drug administration

  3. AUC0-12hTipranavir and Ritonavir

    Time frame: 12 hours after drug administration

  4. Time of Maximum Concentration

    Time frame: up to 72 hours after drug administration

  5. Elimination half-life (t1/2)

    Time frame: up to 72 hours after drug administration

  6. Total body clearance (Cl/F)

    Time frame: up to 72 hours after drug administration

  7. Volume of distribution,

    Time frame: up to 72 hours after drug administration

  8. Number of subjects with adverse events

    Time frame: up to 42 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005 and a primary completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2014
First posted
Oct 1, 2014
Start
Dec 2005
Primary completionActual
Mar 2006
Last update
Oct 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02253862
Responsible party
Sponsor
First posted
Oct 1, 2014
Start date
Dec 2005
Primary completion
Mar 2006
Last update
Oct 1, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tadalafil · Tipranavir · Ritonavir

Start the discussion